Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
Β 

ο»Ώ

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Β 

Major contract win

Β 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

Β 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

Β 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

Β 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

Β 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

Β 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

Β 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutionsΒ to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
CNTBBGDUSDBBGSL
Date   Source Headline
12th Dec 20194:41 pmRNSForm 8.3 - Open Orphan PLC
11th Dec 20194:03 pmRNSForm 8.3 - Open Orphan
11th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 201911:13 amGNWForm 8.3 - Open Orphan
11th Dec 20197:00 amRNSForm 8 (OPD)
10th Dec 20194:43 pmRNSForm 8 (DD) Open Orphan plc
10th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
10th Dec 20199:59 amPRNForm 8.3 - Open Orphan
10th Dec 20197:00 amRNSRule 2.9 Announcement
9th Dec 20191:27 pmRNSTotal Voting Rights
9th Dec 201912:21 pmPRNForm 8.3 - Open Orphan Plc
9th Dec 20197:00 amRNSRecommended All-Equity Offer
25th Nov 20197:00 amRNSEarly adopters signed for Genomic Health DataBANK
18th Nov 20197:00 amRNSContract signed with Carna Bioscience
15th Nov 20197:00 amRNSJefferies 2019 London Healthcare Conference
11th Nov 20197:00 amRNSPreferred Partner Agreement
24th Oct 20197:00 amRNSValue the Markets Webinar
21st Oct 20197:00 amRNSInvestor Event Attendance and Presentation
15th Oct 20197:00 amRNSAgreement signed with Empiric Logic
8th Oct 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Oct 20193:58 pmRNSResult of AGM
1st Oct 201911:08 amRNSHolding(s) in Company
27th Sep 20198:00 amRNSEuronext Growth Dublin Notice
25th Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
23rd Sep 20193:39 pmRNSExercise of Warrants and Issue of Shares
16th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
12th Sep 20197:00 amRNSNotice of AGM
10th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
9th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
3rd Sep 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Sep 20197:00 amRNSUpcoming Investor Events
1st Aug 20197:00 amRNSDirectorate Changes
30th Jul 20198:00 amRNSEuronext Growth Dublin Notice
25th Jul 20197:00 amRNSExercise of Warrants and Issue of Shares
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
12th Jul 20197:00 amRNSIntegumen Shares
9th Jul 20195:26 pmRNSHolding(s) in Company
28th Jun 20198:00 amRNSEuronext Growth Dublin Notice
28th Jun 20197:59 amRNSEuronext Growth Dublin Cancellation Notice
28th Jun 20197:00 amRNSFirst Day of Dealings and Re-admission
25th Jun 20191:24 pmRNSDirectorate Update
14th Jun 201912:13 pmRNSEuronext Growth - Schedule One
14th Jun 201911:00 amRNSSchedule One - Ven Life Sciences Holdings plc
11th Jun 20197:30 amRNSEuronext Growth Dublin Market Restoration Notice
11th Jun 20197:30 amRNSRestoration - Venn Life Sciences Holding Plc
11th Jun 20197:01 amRNSPlacing of Shares
11th Jun 20197:00 amRNSAudited Final Results
10th May 20197:30 amRNSEuronext Growth Dublin Suspension Notice
10th May 20197:30 amRNSSuspension - Venn Life Sciences Holdings Plc
10th May 20197:01 amRNSConditional Acquisition of Open Orphan DAC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.